Improving Outcomes in Diabetes: Focus on SGLT2 Inhibitors. A Medical Experts Discussion

Published: 01 April 2021

  • Views:

    Views Icon 4758
  • Likes:

    Heart Icon 7

Overview

Full programme

Part 2 of 5

Andrew Frankel

Andrew Frankel

Overview

This programme has been created with a view to educate primary care healthcare professionals in the UK to understand when, and for whom, they should prescribe SGLT2 inhibitors and to understand the latest advancements in this drug class.

 

Boehringer Ingelheim Ltd has supported this event as a Medical Education Grant and has had no other involvement in the organisation or the delivery of this programme.

Key Learning Objectives

  • Describe how and when to prescribe SGLT2 inhibitors
  • Identify patients who are suitable for SGLT2 inhibitors
  • Provide appropriate patient education and advice when initiating SGLT2 inhibitors
  • Recall the patient populations in whom SGLT2 inhibitors have proven efficacy and safety

Faculty

  • Dr Jas Gill - GP with Special Interest in Cardiology
  • Dr Andrew Frankel - Consultant Nephrologist
  • Dr Derek Connolly - Consultant Interventional Cardiologist
  • Su Down - Nurse Consultant in Diabetes

More from this programme

Part 1

Welcome and Introductions

Part 2

SGLT2 inhibitors: Initiation in Diabetic Kidney Disease

Part 3

SGLT2 Inhibitors in Heart Failure

Part 4

Practical aspects of initiating in Diabetes

1 session
Su Down Watch now

Part 5

Practical Prescribing

1 session
Jas Gill Watch now

Faculty Biographies

Andrew Frankel

Andrew Frankel

Consultant Nephrologist

Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Over the years he has maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes.  Because of this experience, Dr Frankel has played a significant role in the development of national guidelines on the management of diabetes in the context of kidney disease. He is a regular speaker both locally and nationally and indeed internationally in relation to matters pertaining to diabetes and the kidney.

In collaboration with…

View full profile